aibioSYRE Spyre Therapeutics, Inc.
Spyre Therapeutics (SYRE) news
Top story · Oct 7, 2026 · SEC filing 8-K
Spyre Therapeutics signs a material agreement
Entry into a Material Definitive Agreement On October 5, 2026, Spyre Therapeutics, Inc.
Latest Spyre Therapeutics news
We have not published a story on Spyre Therapeutics yet. When there is news, it will appear here.
What Spyre Therapeutics does
Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. Its pipeline includes extended half-life antibodies targeting α4β7, TL1A and IL-23, which the company develops as monotherapies and as pair-wise combinations. The company describes three strategic pillars: next-generation monotherapies engineered for optimized potency, selectivity and pharmacokinetics; fixed-dose combinations of its engineered antibodies for IBD; and expansion of its anti-TL1A program into additional indications, starting with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. The candidates use Fc domain modifications called YTE substitutions to extend half-life and are formulated as high-concentration, citrate-free products. The company says this could enable quarterly or twice-annual subcutaneous maintenance dosing. The company also describes paradigm-changing IBD combinations of its engineered investigational antibodies, designed to enable superior efficacy, safety and convenience.
| Product or program | What it is | Stage |
|---|---|---|
| SPY001 | Long-acting antibody targeting α4β7 for IBD | |
| SPY002 | Long-acting antibody targeting TL1A, expanding into rheumatic diseases | |
| SPY003 | Long-acting antibody targeting IL-23 for IBD |
Spyre Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net income (loss) | -$155.2 million | -$208.0 million |
| Cash from operations | -$169.3 million | -$157.4 million |
| Cash and equivalents | $85.7 million | $89.4 million |
| Short-term investments | $670.8 million | $513.7 million |
Questions about Spyre Therapeutics
What is the ticker symbol of Spyre Therapeutics?
Spyre Therapeutics, Inc. trades under the ticker SYRE on NASDAQ.
Where is Spyre Therapeutics listed?
Spyre Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:3920; FWB:3920; GETTEX:3920; LS:A3D4LY; LSX:A3D4LY; MUN:3920; SWB:3920; TRADEGATE:3920; XETR:3920.
What is the SEC CIK of Spyre Therapeutics?
The SEC Central Index Key (CIK) for Spyre Therapeutics, Inc. is 1636282. Its filings are on SEC EDGAR.
How many shares does Spyre Therapeutics have outstanding?
88,173,762 shares as of 2026-07-28, per the cover page of its 10-Q filed 2026-08-04.
Which country or territory is Spyre Therapeutics listed under?
Our directory records Spyre Therapeutics, Inc. under United States.
What does Spyre Therapeutics do?
Our directory classifies Spyre Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Spyre Therapeutics?
The ISIN recorded for Spyre Therapeutics, Inc. is US00773J2024.
Does aibio.space cover Spyre Therapeutics?
aibio.space lists Spyre Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Spyre Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What does Spyre Therapeutics develop?
Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. Its pipeline includes extended half-life antibodies targeting α4β7, TL1A and IL-23, which the company develops as monotherapies and as pair-wise combinations.
What is SPY001 from Spyre Therapeutics?
SPY001: Long-acting antibody targeting α4β7 for IBD
What is SPY002 from Spyre Therapeutics?
SPY002: Long-acting antibody targeting TL1A, expanding into rheumatic diseases
What was Spyre Therapeutics's revenue last year?
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Spyre Therapeutics profitable?
Spyre Therapeutics, Inc. reported a net loss of $155.2 million for the fiscal year ended Dec 31, 2025, and used $169.3 million of cash in operations, per its annual report to the SEC.
How much cash does Spyre Therapeutics have?
$1.15 billion in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Investor discussion: Spyre Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Legal
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Legal
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02,8.01). Source
Stock chart
SEC filings and registration
- SEC name
- Spyre Therapeutics, Inc.
- CIK
- 1636282
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- SYRE (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 221 CRESCENT STREET, WALTHAM, MA, 02453
- Phone
- 6176515940
- Shares outstanding
- 88,173,762 as of 2026-07-28 (10-Q filed 2026-08-04)
- Former names
- Aeglea BioTherapeutics, Inc.
Recent filings
Listing details
- Company
- Spyre Therapeutics, Inc.
- Ticker
- SYRE
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US00773J2024
- Other listed symbols
- DUS:3920; FWB:3920; GETTEX:3920; LS:A3D4LY; LSX:A3D4LY; MUN:3920; SWB:3920; TRADEGATE:3920; XETR:3920
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction